Stem cell biotech Magenta bags $50M, strikes licensing deal with Novartis – Boston Business Journal
Endpoints News |
Stem cell biotech Magenta bags $50M, strikes licensing deal with Novartis
Boston Business Journal Magenta, a 26-employee startup, focuses on stem cell transplants, which involve replacing unhealthy cells with healthy cells in patients with cancer and other diseases. The company is trying to make such transplants safer and available for a broad … Magenta Therapeutics Advances Stem Cell Transplantation Strategy with $50 Million Series B Financing, Licensing of … Magenta gains $50M Series B, Novartis candidate and new partnership Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it |
